Pembrolizumab (Immunotherapy Drug) in Combination With Guadecitabine and Mocetinostat (Epigenetic Drugs) for Patients With Advanced Lung Cancer

Clinical Trials

Institution: Memorial Sloan Kettering, Fox Chase Cancer Center, Johns Hopkins Medical Center

Type: Multi-Center Trial


The purpose of this study is to find the best dose of the investigational drugs guadecitabine and mocetinostat to be given safely and effectively with pembrolizumab immunotherapy in patients with metastatic non-small cell lung cancer. Pembrolizumab works by blocking a molecule called PD-1 that shuts down the immune response. Blocking PD-1 can allow the immune system to detect and attack cancer cells. Guadecitabine and mocetinostat are “epigenetic therapies” that work on certain genes that may be turned on or off in cancer. Pembrolizumab is given intravenously (by vein). Guadecitabine is given by subcutaneous (under the skin) injection, and mocetinostat is taken orally (by mouth).

Dates: August 4, 2017 - July 31, 2020

Disease: Lung Cancer


By center:

Memorial Sloan Kettering
Matthew Hellman, MD
[email protected]

Fox Chase
Hossein Borghaei, MS, DO
[email protected]
888-369-2427 or 215-214-4297

Johns Hopkins
Jarushka Naidoo, MBBCh
[email protected]

Page last updated: February 23, 2021

Freedom From Smoking Clinic
Brooklyn, CT | May 31, 2022
Freedom From Smoking - Cleveland, OH Virtual Event
Cleveland, OH | Jun 02, 2022